TFX at a glance
Teleflex Inc (TFX, SEC CIK 96943) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Teleflex Inc (TFX) reported revenue of $2.0 billion (down 34.6% from FY2024) and a net loss of $905.6 million. Diluted EPS was -$20.25.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Teleflex Inc (TFX) shares worth $2.2 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.0B
- −34.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $2.2B · −2 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $567.8M, up $0.9M, or 0.2% YoY
- Gross margin 65.0% vs 51.5% YoY, aided by tariff refunds and nonrecurring inventory step-up
- Best segment Vascular: revenue $243.5M, up 4.7%; worst Interventional: revenue $210.3M, down 2.6%
- Operating cash flow $234.8M vs $10.3M; $555.0M share repurchases and $1.0B debt reduction
- Outlook: tariff impacts remain uncertain; Acute Care and IU sale may extend into 2027
Risk Factors
- Newly added shareholder activism risk: Irenic’s March 27, 2026 campaign seeks board changes and strategic-alternatives review
- Most material update: activist proposals could divert management attention and increase advisory costs
- Market risk: activism may trigger stock-price volatility unrelated to business fundamentals
- Operational risk: perceived uncertainty could hinder retention of qualified personnel and customer relationships
AI summary of the TFX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1
- Non-GAAP metrics emphasize pro forma revenue, constant-currency growth and adjusted diluted EPS
Item 7.01: Regulation FD Disclosure
- Slide presentation supports Teleflex’s November 5, 2026 conference call on third-quarter results
- Results cover the quarter ended September 30, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $567.8M, up 3.0% pro forma constant currency, with Vascular +4.6% and Surgical +5.1%
- Adjusted EPS $2.63 versus $1.89, while adjusted operating margin reached 25.0%
Item EX-99.2: Item EX-99.2
- Q3 adjusted EPS $2.63, up 39.2% year over year, supported by higher margins, lower interest expense, fewer shares and tariff refunds
- OEM divestiture closed for $1.5B proceeds, $1.25B after tax, funding planned debt reduction and share repurchases
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from eight to nine directors, adding governance capacity and healthcare-industry expertise
- Sean M. Salmon elected director, bringing 21 years of Medtronic leadership across cardiovascular and diabetes businesses
Item 7.01: Regulation FD Disclosure
- Board appointment announcement for Mr. Salmon, effective September 8, 2026
- Governance change may influence board oversight, strategy and shareholder representation
Item EX-99.1: Item EX-99.1
- Sean M. Salmon appointed to Teleflex’s nine-member Board, effective September 8, 2026
- Eight of nine directors now independent, supporting governance credibility and board refreshment
Item 8.01: Other Events
- $250 million accelerated share repurchase under Teleflex’s existing $1 billion authorization
- Initial share delivery valued at 80% of the repurchase price on August 10, 2026
AI summaries of TFX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TFX
Don't miss the next TFX filing
- Alerts as it files. A push when TFX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TFX, by share count.
- Ask anything. An AI agent that reads every TFX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Salmon Sean | A | Sep 8, 2026 | 4,444 | - |
| Salmon Sean | A | Sep 8, 2026 | 674 | - |
| Weidman Jason R. | A | Jun 8, 2026 | 26,071 | - |
| Weidman Jason R. | A | Jun 8, 2026 | 53,983 | - |
| RANDLE STUART A | A | Jun 8, 2026 | 4,663 | - |
| RANDLE STUART A | A | Jun 8, 2026 | 2,192 | - |
| RANDLE STUART A | A | Jun 8, 2026 | 995 | - |
| RANDLE STUART A | F | Jun 7, 2026 | 4,054 | $129.84 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.0B | $2.0B |
| Gross Profit | - | $1.7B | $1.1B |
| Operating Income | - | $151.0M | $118.4M |
| Net Income | - | $69.7M | -$905.6M |
| Gross Margin | - | 55.9% | 56.2% |
| Op. Margin | - | 5.0% | 5.9% |
| Net Margin | - | 2.3% | -45.4% |
| Balance Sheet | |||
| Total Assets | $7.5B | $7.1B | $6.9B |
| Equity | $4.4B | $4.3B | $3.1B |
| ROE | - | 1.6% | -29.0% |
| Per Share | |||
| EPS | - | $1.48 | $-20.25 |
| Cash Flow | |||
| Operating CF | - | $638.3M | $96.7M |
| CapEx | - | $126.4M | $95.2M |
Source: XBRL data in Teleflex Inc (TFX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TFX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $2.19B |
| Q2 2026 | 34 | $2.69B |
| Q1 2026 | 33 | $2.26B |
| Q4 2025 | 31 | $2.55B |
| Q3 2025 | 32 | $2.63B |
| Q2 2025 | 32 | $2.30B |
| Q1 2025 | 30 | $2.06B |
| Q4 2024 | 28 | $2.01B |
- Invesco Ltd+535.3K (+93%)
- Renaissance Technologies LLC+65.5K (+87%)
- Ameriprise Financial+42.7K (+14%)
- D.E. Shaw & Co+39.5K (+295%)
- Dimensional Fund Advisors+26.5K (+2%)
- Goldman Sachs Group−746.3K (-82%)
- Citadel Advisors LLC−668.8K (-59%)
- Millennium Management−368.1K (-26%)
- JPMorgan Chase & Co−306.6K (-78%)
- BlackRock−219.0K (-4%)
- Two Sigma Investments+19.4K
- Baupost Group−1.41M
- Blackstone Group−24.1K
- FMR LLC (Fidelity)−7.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 252 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TFX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | - | |
| 8-K | Jun 1, 2026 | - | - | |
| 8-K | May 27, 2026 | - | - | |
| 8-K | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | - | |
| 8-K | May 7, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 8-K | Mar 17, 2026 | - | Analysis | - |
| 4 | Mar 5, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TFX SEC filings: frequently asked questions
Which institutions hold TFX stock?
As of September 30, 2026, the largest Teleflex Inc (TFX) holders among the 13F filers tracked by SignalX were BlackRock ($651.8 million), Vanguard Portfolio Management LLC ($290.7 million), Vanguard Capital Management LLC ($238.2 million), State Street Corp ($180.4 million), Dimensional Fund Advisors ($147.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TFX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Teleflex Inc (TFX) reported revenue of $2.0 billion (down 34.6% from FY2024) and a net loss of $905.6 million. Diluted EPS was -$20.25. The figures come from the XBRL data in the 10-K.
What did TFX report in its latest 8-K?
Teleflex Inc (TFX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1.
What are the latest TFX SEC filings?
Teleflex Inc (TFX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 10, 2026.
What is TFX's SEC CIK number?
Teleflex Inc (TFX)'s SEC Central Index Key (CIK) is 96943. EDGAR lists every TFX filing under that number.
Ask anything about TFX
The research agent reads TFX's filings, financials, insider trades and 13F holders, then answers with sources.